MICHELE HULL: Open Payments
NPI 1235772112 · MOUNT TABOR, NJ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$2,089 in 146 payments from 15 companies in 2025. Trend: 2023 $789 · 2024 $870 · 2025 $2,089
Food & beverage: $2,089
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 20 | $389 |
| Neurocrine BioSciences, Inc. | 17 | $275 |
| Teva Pharmaceuticals USA, Inc. | 13 | $216 |
| Vanda Pharmaceuticals Inc. | 11 | $208 |
| Otsuka America Pharmaceutical, Inc. | 14 | $187 |
| ABBVIE INC. | 33 | $166 |
| Janssen Pharmaceuticals, Inc | 9 | $160 |
| Lundbeck LLC | 9 | $146 |
| Luye Pharma (USA) Ltd. | 6 | $111 |
| E.R. Squibb & Sons, L.L.C. | 4 | $91 |
Products named: ARISTADA, INGREZZA, REXULTI, FANAPT, VRAYLAR, UZEDY, INVEGA SUSTENNA, ERZOFRI EXTENDED-RELEASE.
Industry payments across NJ — which companies pay providers there.
